Drug developer NanoViricides (OTCBB: NNVC.OB) said Monday that it will present its anti-flu studies at the TechConnect World 2011 Conference, being held June 13 to 16 at the Hynes Convention Center in Boston.
The company has completed several animal studies on its anti-flu candidates to date, and has improved results with each study, it said.
In the most recent, NanoViricides reported that post-infection treatment with its FluCide drug candidate achieved 1,000 fold reduction in the levels of the infectious virus in the lungs of mice.
In addition, two of the FluCide candidates maintained the reduced lung viral load throughout the duration of the 21 study. The trial also showed increased survival rates and reduced lung inflammation, when compared to current treatment options like Tamiflu.
The company will present the study data and discuss the significance at the conference, in a talk led by president and chairman, Dr. Anil R. Diwan, entitled "Nanoviricides as Anti-Influenza Agents".
The oral presentation is scheduled for 11:20 am on June 16, in the session called "Bio Nano Materials: Novel bio nano materials and applications".
For more information on the conference, visit http://www.techconnectworld.com/World2011/thursday.html.
NanoViricides is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, among others.